

Clinical Trials

BioSpace - FREE Daily Newsletters GenePool, Career Insider, Clinical

Focus and Deals & Dollars

Biotechnology

Pharmaceutical

NEW! BioSpace Forum A Community Discussion Board

Hotbed Communities Regional News, Info & Maps

Bio NC™ BioCapital™ <u>BioMidwest</u>™ <u>BioGarden</u>™ (NJ) Biotech Bay™ Biotech Beach™ <u>Genetown</u>™ Pharm Country™

Career Center

Discover Your Future

Southern Pharm™

For Job Seekers Search Jobs Post Resume

Career Fairs

For Employers Post a Job Search Resumes

NEW! Medical Device & Diagnostics Channel Industry News & Updates

Diversity Channel The Culture of Life Science

BioPharm Insight Investigational Drug Data

Prescription Drug Forecasts Drug Licensing Deals

BioZones

Building Blocks For Biotech

BioCrossroads™ (IN) Bio UK™ Isla de Biotech™ (PR)

For Investors Investment In Knowledge

Quote

<u>Newsletters</u> <u>Forums</u> BioSpace Bellwethers <u>Stocksort</u> BioSpace Movers By Hotbed **IPOs IPO News** Deals & Dollars Clinical Development News Brokerage Ratings Personal Portfolio Venture Reports

Companies

Biotech Company Details

Search Companies <u>Suppliers</u> Service Firms

Start-Ups Track Newcomers in Biotech

Start-Up Jobs **Start-Up Companies**

October 06, 2006 03:51 PM Eastern Time CepTor Reports Two Issues Remain to Move Myodur IND Forward

Research and Science

- FDA Instructs Company to Address Two Issues Before Granting Clearance to Begin Human Muscular Dystrophy Trials -

HUNT VALLEY, Md.--(BUSINESS WIRE)--CepTor Corporation (OTC BB:CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced today that its Investigational New Drug application (IND) for Myodur to be used in Duchenne muscular dystrophy trials remains on hold. In a teleconference with the FDA, the agency reported that there are two remaining issues that it would like the Company to address before moving into human trials. The Company reported that the remaining two items are straightforward and addressable.

About CepTor Corporation

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. CepTor's primary efforts are currently focused on moving its lead product, Myodur, into clinical trials for Duchenne muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP) and amyotrophic lateral sclerosis (ALS). More information about CepTor can be found at www.ceptorcorp.com.

The press release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involves a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation on our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. The Company disclaims any obligation to update any forwardlooking statement as a result of developments occurring after the date of this press release.

Contacts

CepTor Corporation Donald W. Fallon, 410-527-9998

Fax: 410-527-9867 dfallon@ceptorcorp.com

Wolfe Axelrod Weinberger Assoc. LLC Donald C. Weinberger,


212-370-4500 Fax: 212-370-4505 don@wolfeaxelrod.com


Media:

Alisa D. Steinberg, 212-370-4500

Fax: 212-370-4505 alisa@wolfeaxelrod.com







Start-Up Events

Science Center
Scientific Community Content
Quick Lit Search

Industry Events
Biotech Calendar Of Events

MarketPlace

A Buyers Guide To Biotech

Resources
Valuable Industry Information
Real Estate

Customer Care

BioSpace Contact Information

Terms of Use | © Business Wire 2006

| BioPharm Insight | News | Career | Hotbeds | Companies | FREE Magazines | | Investor | Start-Ups | Expert Search | Science Center | Events | Marketplace | | Resources | Real Estate | Search | GenePool | Help | Home |

Advertising Opportunities On BioSpace Sponsorship Opportunities On BioSpace BioSpace Information

Post a Job on BioSpace
Post an Event on BioSpace
Post your News on BioSpace
Post a Company Profile on BioSpace